# Study to Evaluate the Safety and Anti-tumor Activity of SCC244

> **NCT03466268** · PHASE1 · COMPLETED · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Gumarontinib Tablets

## Key facts

- **NCT ID:** NCT03466268
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-14
- **Primary completion:** 2023-01-09
- **Final completion:** 2023-01-09
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466268, "Study to Evaluate the Safety and Anti-tumor Activity of SCC244". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03466268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*